Third Time’s Not The Charm For King’s Pursuit of Alpharma

As King Pharmaceuticals tries to move past the hit from the entry of generic competition for Altace and overall lackluster second quarter sales figures, the firm has embarked on a plan to become a powerhouse specialty therapeutic pain company, and a central piece of that plan is the acquisition of Alpharma. But Alpharma will have none of it